Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior ...
Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する